43 results about "Mononuclear Blood Cell" patented technology

Using RNA samples from mononuclear blood cells, gene sequences were identified that can be used to identify patients with IBD, and then distinguish patients with Crohn's disease from those with ulcerative colitis. Sequences were identified whose overexpression was distinct to patients with IBD, Crohn's disease, and ulcerative colitis when compared to patients with non-IBD intestinal disorders. Additionally, cluster analysis was used to identify twenty-five sequences that are IBD-related, and whose transcription pattern can be used in a microarray analysis to identify patients with IBD with a sensitivity of 84% and a specificity of 100%. Cluster analysis also identified thirty-six genes that could be used to distinguish patients with Crohn's disease from those with ulcerative colitis with a sensitivity of 89% and a specificity of 80%.

The invention relates to a kit for high-purity high-recovery separation in vitro of allogeneic peripheral blood mononuclear cells and an application method of the kit. The allogeneic mononuclear cells separated by the kit can be used for immunotherapy of unexplained habitual abortion. The kit comprises a reagent I, namely a peripheral blood thinner, a reagent II, namely an erythrocyte sedimentation solution, a reagent III, namely mononuclear cell separating solution and a reagent IV, namely a mononuclear cell washing solution. The method for separating the allogeneic peripheral blood mononuclear cells by using the kit comprises the following steps: anticoagulation pre-centrifugation; erythrocyte initial reaction; erythrocyte sedimentation; two-step separation of the mononuclear cell separating solution; secondary purification of mononuclear cells; bacteria detection; mononuclear cell cryopreservation. According to the technology, the mononuclear cell recovery rate can achieve more than 90 percent, the purity can achieve more than 95 percent, the survival rate can achieve more than 98 percent, and the service efficiency of the peripheral blood mononuclear cells is greatly improved. Plasma is removed through the step of anticoagulation pre-centrifugation. Compared with the conventional separation technology, the dose of the separation reagent is reduced, and the separation cost is effectively reduced.

The invention relates to the technical field of biomarkers, in particular to application of a peripheral blood mononuclear cell hsa-miR-874-3p as a marker of active tuberculosis. The hsa-miR-874-3p issignificantly up-regulated in peripheral blood mononuclear cells from patients with active tuberculosis and a human monocyte cell line THP-1 infected with tuberculosis, and the up-regulated hsa-miR-874-3p possibly acts on ATG16L1 mRNA in mononuclear macrophages to regulate macrophage autophagy and participate in the infection process of Mtb. The up-regulated hsa-miR-874 has certain significance for the early diagnosis of APTB patients. The detection of the expression condition of hsa-miR-874 in patients with APTB using a qRT-PCR method can diagnose the disease. A new molecular target for clinical diagnosis and treatment is provided, and the development of new drugs is facilitated.

The invention discloses a cryopreservation solution and a cryopreservation method for human peripheral blood mononuclear cells, and belongs to the technical field of cell biology. The cryopreservationsolution comprises the following components: 8% of dimethyl sulfoxide, 70% of autologous plasma, 10% of hydroxyethyl starch and 12% of human serum albumin. The specific cryopreservation procedure comprises the following steps: a, waiting at 4 DEG C until the product is put in; b, cooling to 0 DEG C at a speed of 1 DEG C/min, and keeping for 5 minutes; c, cooling to -10 DEG C at a speed of 1 DEG C/min, and keeping for 5 minutes; d, cooling to -45 DEG C at a speed of 1 DEG C/min, and keeping for 20 minutes; e, cooling to -90 DEG C at a speed of 5 DEG C/min, and keeping for 5 minutes; and f, ending. According to the cryopreservation solution and the cryopreservation method, the cell activity and the recovery rate after cryopreservation recovery can be remarkably increased, high-quality NK cells with high purity, high cell activity and high amplification factor are induced and cultured, and a favorable guarantee is provided for clinical treatment of the NK cells.

Methods (300), devices, and systems of processing blood are describes. The method (300) comprises the steps of: obtaining (312) blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collection (314) bulk mononuclear blood cells from the blood by leukapheresis using the blood processing device in the closed loop; and enriching (316) concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.

The invention provides a method for separating and culturing peripheral blood mononuclear cells, and relates to the field of biotechnology cell culture. The separation and culture method of the peripheral blood mononuclear cells comprises the following steps: S1, collecting peripheral blood, S2, carrying out centrifugal separation, S3, extracting peripheral blood mononuclear cells, S4, purifying the peripheral blood mononuclear cells, S5, preparing a cell culture medium, S6, carrying out cell culture, and S7, performing preservation. An ALK inhibitor and a GSK-3 inhibitor are arranged, cytopathy in a cell culture process can be inhibited, excessive activation of pathological cells is prevented and rapid proliferation is carried out, animal serum is not added in the culture process, so thatthe possibility of obtaining viruses from animals in the culture process is reduced, the safety in the culture process is ensured, and peripheral blood mononuclear cells are cleaned and purified formultiple times after separation is completed, so that the cultured cells basically do not contain other impurity cells, and the cultured cells are relatively pure.

The invention provides a separation method for separating peripheral blood mononuclear cells, and particularly relates to the field of biological medicines. The separation method comprises the following steps: S1, preparation of a separation tube: firstly, adding 2-6 ml of Percoll or polysucrose or meglumine diatrizoate cell separation liquid with the density of 1.075-1.0796 g/ml into a centrifugal tube, sucking 0.5-1.5 ml of separation gel with the density of 1.06-1.07 g/ml, adding the separation gel into a tube opening of the centrifugal tube, and carrying out horizontal centrifuging for 1-3minutes at room temperature under the centrifugal force of 800-1200 g, so that the separation gel forms an isolation layer on the liquid surface of the Percoll or polysucrose or meglumine diatrizoatecell separation liquid, and preparation of the separation tube is finished; and S2, separation of the peripheral blood mononuclear cells: adding 2-6 ml of anticoagulant whole blood into the preparedseparation tube, and carrying out horizontal centrifuging for 8-12 minutes at room temperature under the centrifugal force of 800-1200 g; sucking and discarding the uppermost liquid to remove cell fragments and platelets, directly pouring the liquid above the isolation layer into a collection tube, carrying out centrifuging for 4-6 minutes at room temperature under the centrifugal force of 600-1000 g, and resuspending the cells by using PBS to obtain the peripheral blood mononuclear cells. According to the separation method, it can be ensured that the anticoagulant whole blood can be absolutely not mixed with a cell separation medium after being added, and other cells are not polluted when the peripheral blood mononuclear cells are harvested.

The invention discloses a separation method of peripheral blood mononuclear cells. According to characteristics of separating a large number of blood samples, the method comprises steps of removing most of red blood cells by using a hydroxyethyl starch precipitation method, conducting natural sedimentation in the air, and further purifying the mononuclear cells by using a Ficoll density gradient centrifugation method to obtain PBMC with more than 95% of purity and more than 90% of activity. Compared with methods without natural sedimentation in the air, the cells obtained by the separation method of the present invention are higher in activity and purity.

The present invention provides a compound represented by the formula:

wherein R¹ is a 5- or 6-membered ring which may be substituted;

R³ is a hydrogen atom, a lower alkyl group or a lower alkoxy group;

Z¹ is a 5- or 6-membered aromatic ring;

Z² is a group represented by -Z^2a-W²-Z^2b wherein Z^2a and Z^2b are each O, S(O)_m (wherein m is 0, 1 or 2), an imino group, or a bond; and W² is an alkylene chain which may be substituted; n is an integer of 0 to 4;

Y is O, S(O)_p (wherein p is 0, 1 or 2), CH₂ or NR⁴ (wherein R⁴ is a hydrogen atom, a hydrocarbon group, a heterocyclic group, or an acyl group); and

R² is (1) an amino group, in which the nitrogen atom is converted to quaternary ammonium or oxide, (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as a ring-constituting atom, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, and the like, or a salt thereof. The compound has excellent CCR5 antagonist activity and is useful as a prophylactic and/or therapeutic medicine for HIV infection in human peripheral mononuclear blood cells, especially AIDS.

The invention relates to the technical field of cell culturing, and particularly relates to an NK cell culturing solutions and culturing method. The invention discloses the NK cell culturing solutions, and the culturing solutions can perform compounding of IFN-gamma and IL-15 and perform compounding of IL-2, IL-1alpha and CD3 monoclonal antibodies, and based on combined effect, efficient transformation from peripheral blood mononuclear cells to NK cells is stimulated, the multiplying power of the NK cells is increased, and more NK cells are obtained, and moreover, contents of CD3-CD56+ and CD3+CD56+ are high, and the killing activity is high. The NK cell culturing solutions provided by the invention are illustrated that the toxic activity of the cells is obviously improved while the proliferation quantity of the NK cells is increased at the same time.

The invention discloses application of a preparation for detecting peripheral blood mononuclear cells circGSAP in preparation of a kit for predicting the survival rate of patients with idiopathic pulmonary hypertension. It is found for the first time that the expression levels of the peripheral blood mononuclear cells circGSAP of IPAH survivors and non-survivors are different. The peripheral blood mononuclear cells circGSAP can be used as an independent survival rate predictor, and provides a reference for evaluating the severity and clinical prognosis of the disease progress of the IPAH patient.

The invention relates to the technical field of cell membrane protein detection, in particular to a detection method and application of a human peripheral blood mononuclear cell membrane surface transporter. The method comprises the following steps: (1) separating human peripheral blood mononuclear cells; (2) extracting peripheral blood mononuclear cell membrane protein; (3) performing membrane protein pretreatment; and (4) performing nanoliter liquid phase tandem high-resolution mass spectrometry detection, and calculating the expression quantity of the transporter on the surface of the PBMC membrane. The method not only can be used for detecting the transporter on the surface of the PBMC membrane of the organ transplantation patient, but also can be used for detecting the transporter on the surface of the PBMC membrane of other immune disease patients; and the transporter on the surface of the PBMC membrane can be detected only by 1-3 mL of a whole blood sample, multiple transporters can be detected at the same time, and the flux is high.

The invention relates to the technical field of biomedical technology, in particular to the application of TLR7 and TLR8 as prophylactic and therapeutic targets of IgA nephropathy and the applicationof inhibitor of TLR7 in prophylactic and therapeutic treatment of IgA nephropathy. The invention proves that the expression level of TLR7 gene and TLR8 gene in peripheral blood mononuclear cells (PBMCs) of IgA nephropathy patients is significantly increased compared with healthy control and disease control, when activated by TLR7 and TLR8 co-ligand R848, more IgA1 antibodies were produced, and abnormal O-glycosylation of the IgA1 antibodies were aggravated. Compounds of formula C<16>H<19>N<3>O<2> act as inhibitors of TLR7, inhibiting the ability of peripheral mononuclear blood cells to synthesize IgA1 and decreasing the abnormal O-glycosylation of these IgA1 molecules. Glycosylation. TLR7 and TLR8 are novel targets for the treatment of IgA nephropathy and have great clinical value.

A method to determine the activity level of autoimmune diseases, the method including a) to supply a biological sample; b) to determine the TßRII-A, TßRII-B and TßRII-Se isoforms level of the biological sample; c) calculate the activity level by performing the quotient between the TßRII-Se level and the level of the addition of TßRII-A y TßRII-B. The isoforms level are measured by detecting the polypeptides of the isoforms or the mRNA of the isoforms in the isolated circulating mononuclear blood cells by means of, for instance, RT-qPCR. The ΔCt of each splice variants individually showed a correlation with autoimmune disease activity. Additionally, a similar correlation with autoimmune disease activity was obtained when the ΔCt of TβRII-SE was added to the ΔCt of TβRII-A and the ΔCt of TβRII-A.

The invention discloses an umbilical cord blood mononuclear cell separation method and an application thereof, and belongs to the technical field of cell separation. According to the method, only umbilical cord blood and a Ficoll reagent need to be mixed and subjected to standing treatment, a layering liquid is obtained, then cells of a middle leukocyte layer are sucked and washed, and obtained sediment contains umbilical cord blood mononuclear cells. The method disclosed by the invention adopts a standing mode, is easy to operate and short in consumed time, avoids damage of centrifugation tocells, and ensures the survival rate of the cells. According to the method, blood does not need to be diluted, and consumed time is shorter. According to the method, the technical requirements on experimenters are reduced, and a more stable separation effect can be obtained.

The invention provides application of HIPK2 in sepsis prediction and diagnosis, belongs to the technical field of biomedicine and disease diagnosis, and provides application of HIPK2 in preparation of a sepsis risk prediction, diagnosis and disease course monitoring reagent. The invention discloses an application of HIPK2 in preparation of a septicemia prediction and diagnosis reagent, and verifies that the transcriptional level of HIPK2 in peripheral blood mononuclear cells of a septicemia patient is significantly reduced, and HIPK2 is negatively correlated with a pro-inflammatory gene IL1B and positively correlated with an anti-inflammatory gene IL10; the cellular level experiments find that HIPK2 can inhibit generation of pro-inflammatory cytokines; therefore, the probability that healthy people with low expression of the HIPK2 develop into septicemia during microbial infection can be increased, so that the HIPK2 can be used as a potential septicemia prediction and diagnosis biomarker. According to the invention, a theoretical basis and a new detection method are provided for septicemia prediction and diagnosis.